Aegerion Pharmaceuticals, Inc. Logo Image

Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. has reached its limit for report views.

Please check back to see if Aegerion Pharmaceuticals, Inc. has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2015 Annual Report and Form 10K

Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

About Aegerion Pharmaceuticals, Inc.

201-500 Employees
Based in Cambridge, Massachusetts

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH.

Ticker:
AEGR
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Drug Manufacturers - Major (See More Drug Manufacturers - Major Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol